Kornimate/medical-research-clean huggingface dataset:
stellate ganglion block in preventing cerebral vasospasm secondary to subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage, Aneurysmal; Cerebral Vasospasm

Summary: to investigate whether the stellate ganglion block is helpful in relieving cerebral vasospasm during aneurysmal coil embolism surgery. the effect was assessed by transcranial doppler (tcd).


Eligibility criteria:
inclusion criteria: * 1.emergency patients with subarachnoid hemorrhage caused by ruptured aneurysm, aged 18-65 years; 2. asa : ii-iv grade, hunt-hess : i-iii grade 3. for the first case, the operation time is within 24 hours. 4.after signing informed consent, underwent interventional intravascular embolization exclusion criteria: * 1. patients with severe bleeding disorders; 2. patients with trauma and local infection risk in the nerve block area; 3. patients with previous aneurysm surgery and unruptured aneurysm; 4. aneurysm located in middle cerebral artery; 5. patients with unconsciousness cannot cooperate with the block operation; 6. those with a history of mental illness and epilepsy; 7. those who have a history of severe cardiovascular and cerebrovascular diseases and severe organ diseases;

Keywords: stellate ganglion block subarachnoid hemorrhage cerebral vasospasm transcranial doppler ultrasonography
a multiple-dose study of the safety and tolerability of regn88(sar153191) in rheumatoid arthritis subjects

Conditions: Rheumatoid Arthritis

Summary: this is a randomized study of the safety and tolerability of multiple doses of regn88 in rheumatoid arthritis patients who are receiving treatment with methotrexate.

this is a multi-centered, randomized, double-blind, placebo-controlled, ascending parallel-group study of the safety and tolerability of regn88 in patients with rheumatoid arthritis who are receiving concomitant methotrexate. this study will be conducted in 3 parts, and will include a total of 6 dose cohorts. part b will not begin until the safety of part a has been assessed. part c will not begin until enrollment in part b is complete.

Eligibility criteria:
inclusion criteria: * patients with an established diagnosis of rheumatoid arthritis * patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks exclusion criteria: * persistent chronic or current active infections * patients who have taken anakinra within 2 weeks * patients who have taken etanercept, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 4 weeks * patients who have taken adalimumab within 6 weeks * patients who have taken abatacept, azathioprine, cyclophosphamide or infliximab within 12 weeks * patients who have taken leflunomide or rituximab within 6 months * patients who have had prior treatment with tocilizumab or any other anti-il-6 medication * significant arthritis or other medical condition that could interfere with study evaluations * participation in any clinical research study evaluating another investigational drug within 30 days
flurbiprofen axetil as an adjuvant to pre-emptive scalp infiltration

Conditions: Postoperative Pain

Summary: post-craniotomy pain remains a major challenge in patient care following neurosurgery.flurbiprofen axetil (fa), as an injectable nonselective cyclooxygenase inhibitor, is a widely prescribed nsaid for postoperative pain. as fa is highly lipophilic by merging into emulsified lipid microspheres, it has a high affinity to the surgical incision and inflammatory tissues to achieve targeted drug therapy and prolonged duration of action, thus providing a basis for its local use to achieve efficacy and safety comparable to or greater than systemic administration. in this study, we attempt to evaluate the clinical effects of fa as an adjunct to ropivacaine in pre-emptive scalp infiltration to prevent or reduce pain after craniotomy.


Eligibility criteria:
inclusion criteria: 1. age minimum 18 years; 2. asa physical status of i - ii; 3. body mass index (bmi) of 15 - 30; 4. scheduled for supratentorial craniotomy under general anesthesia; 5. anticipated tracheal extubation, recovery of consciousness and orientation within 2 hours after craniotomy. exclusion criteria: 1. glasgow coma scale \<15; 2. unable to use the pcia device or comprehend the pain nrs; 3. history of opioid dependence, chronic headache or intake of any drugs with known analgesic properties within the 24 hours before surgery; 4. history of craniotomy or scalp infection; 5. any contraindication to flurbiprofen axetil, such as gastrointestinal ulcer, coagulation disorders, renal dysfunction, heart failure and ischemic heart disease; 6. history of allergy to any drug used in the study; 7. pregnancy and breastfeeding.
validity and reliability of the 2-minute walk test in individuals with a spinal cord injury

Conditions: Spinal Cord Injuries

Summary: there exist a variety of outcome measures to asses gait function in individuals with a spinal cord injury (sci). the most established measures are the 10-meter walk test (10mwt) and the 6-minute walk test (6mwt). they are used to assess treatment efficacy and recovery of gait function in individuals with sci. however, the 10mwt is appropriate for poor walkers but not sensitive in good walkers and the 6mwt can be time-consuming and is very demanding for severely impaired patients. therefore the 2-minute walk test (2mwt) has gained more attention in the sci field. the 2mwt has been established in numerous neurological diseases and has shown to correlate with the 6mwt in patients with neuromuscular disease, multiple sclerosis and stroke. though the 2mwt has not yet been validated in individuals with sci. a limitation that affects all timed walking tests is that they suffer from limited information about gait quality (i.e. how walking function is achieved). being able to receive information on the gait quality of a patient can help to understand the underlying mechanisms of walking improvements after an intervention (e.g. compensation vs recovery). the research in the field of inertia measuring units (imu) develops and advances very rapidly at the moment resulting in the possibility to perform a gait analysis with a simple imu setup. however, the reliability of such measurement setups has not yet been shown in individuals with sci. the primary aim of this study is to test the validity and reliability of the 2mwt in the sci population. additionally, it will be investigated if a simple sensor setup can give additional reliable information about the gait pattern of individuals with sci.


Eligibility criteria:
inclusion criteria: * participants fulfilling all of the following inclusion criteria are eligible for the study: * informed consent as documented by signature (appendix informed consent form) * at least 18 years old * spinal cord injury * able to walk with a speed of at least 0.17m/s with or without walking devices and or bracing exclusion criteria: * current orthopaedic problems of lower limbs * history of severe cardiac condition * premorbid major depression or psychosis * unlikely to complete the intervention or return for second visit * enrolment of the investigator, his/her family members, employees and other dependent persons
acl reconstruction: clinical outcome

Conditions: ACL Injury

Summary: the study is intended to include all patients who will undergo surgical reconstruction of the anterior cruciate ligament (acl). the patients will be monitored and evaluated preoperatively and also at 6 months and 1, 2 and 5 years after the intervention through a clinical visit or telephone interview. such assessments will include the administration of questionnaires to determine the patient's functional symptoms and the objective examination of the knee during a medical examination to quantify its stability.

the literature presents a number of studies on the reconstruction of the anterior cruciate ligament, as well as numerous registers, but the identification of factors and parameters determining the clinical outcomes remains largely debated. the study aims to offer new elements to analyze this treatment and potentially identify the factors responsible for the outcomes and the factors useful to optimize the clinical outcome in the future. in fact, in addition to collect patient data in terms of features and clinical-functional status, objective data will be documented and correlated. in particular the quantification of knee laxity will be performed using an innovative device based on the use of inertial sensors (a methodology recently developed and already validated at the istituto ortopedico rizzoli). the study is intended to include all patients who will undergo surgical reconstruction of the anterior cruciate ligament (acl). these patients will be followed and evaluated preoperatively, at 6 months and at 1, 2 and 5 years after surgery during a clinical visit or a telephone interview. such evaluations will include the submission of questionnaires to determine the patient's functional symptoms and also knee joint assessment during a medical examination to quantify the knee joint stability. moreover, the following clinical scores will be adopted: ikdc-subjective, ikdc-objective, sf12, marxs, koos, tegner, vas for pain assessment, eq-vas for overall health status assessment. also it will be recorded the lapse of time for returning to work and sports, the degree of patient satisfaction,the adverse events, the failures and any new treatments on the same site.

Eligibility criteria:
inclusion criteria: 1. patients who have provided informed written written consent; 2. patients aged between 18 and 60; 3. patients undergoing reconstructive surgical treatment of the anterior cruciate ligament (acl) exclusion criteria: 1. patients unable to understand and to want; 2. patients who have not signed informed consent;
a clinical investigation to evaluate the orkla corn plaster

Conditions: Corns

Summary: this is a prospective, randomized, controlled, open-labelled investigation to assess performance and safety of orkla corn plaster in subject with corns. the hypothesis is that there is an improvement in the size of corns at day 28 compared to baseline.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form 2. \>18 years of age 3. presence of corn(s) confirmed by investigator 4. corn included into investigation shall not have been subject to any other treatment 1 month prior to study enrolment. exclusion criteria: 1. pregnant or lactating women at time of enrolment 2. subjects with hypersensitivity to salicylic acid/salicylates, polyethylene foil, acrylic adhesive, viscose/polyethylene fibers and azorubine 3. subjects diagnosed with diabetes 4. subjects with poor peripheral blood circulation 5. subjects with renal dysfunction (egfr \<60 ml/min/1.73 m2) 6. subjects with ongoing skin disease in the area where the index corn is located. 7. subjects with any other condition that as judged by the investigator may make follow-up or investigations procedures inappropriate 8. any subject that according to the declaration of helsinki is unsuitable for enrollment
bnp pharmacodynamics and effects on metabolism in lean and obese subjects

Conditions: Obesity; Cardiovascular Disease; Hypertension; Diabetes

Summary: the purpose of this study is to collect data to help researchers better understand the various causes of obesity, which may lead to the development of new obesity treatment options.

obesity is major metabolic health concern and the potential beneficial effects of natriuretic peptides, specifically b-type natriuretic peptide (bnp) on adipocyte biology, energy expenditure and body weight could be of great significance. this study will provide insight into the mechanisms of dysregulation of the natriuretic peptides system in obesity and will contribute to delineate the roles and the clinical importance of bnp in the treatment of obesity.

Eligibility criteria:
inclusion criteria: * age 18-65 years, inclusive * men and women * able to provide written, informed consent * weight stable (± 3 kg) during the 3 months prior to enrollment * bmi ≤ 25 kg/m2 for lean subjects or ≥ 30 kg/m2 for obese subjects exclusion criteria: * 1) diagnosed with any of the following co-morbidities: a) coronary artery disease, angina or heart failure, b) diabetes, c) bleeding disorders, d) infections, e) hepatitis and/or cirrhosis, f) severe asthma or chronic obstructive pulmonary disease (copd), g) renal insufficiency, h) bariatric surgery, i) inflammatory bowel disease or malabsorption, j) cancer within the last 3 years (except non-melanoma skin cancer or treated cervical carcinoma in situ), k) psychiatric or eating disorders, l) untreated or inadequately controlled thyroid or other endocrine disorders, m) active rheumatoid arthritis or other inflammatory rheumatic disorder * pregnant or nursing women * presence of clinically significant abnormalities on electrocardiogram; * smoking * known hypersensitivity to nesiritide or any of its excipients * poor intravenous access * use of medications: a) nitrates, b) beta-blockers, c) digoxin, d) anti-diabetic agents, e) oral, injected or chronic topical steroids (inhaled steroids for mild asthma are acceptable), f) chronic use of aspirin or other non-steroidal anti-inflammatory drugs, including cox-2 inhibitors, g) other drugs known to affect immune or metabolic function and h) orlistat, phentermine or other weight loss or anorectic agents. * your blood pressure at your screening visit is less than or equal to 100/60 or greater than or equal to 160/100.

Keywords: b-type natriuretic peptide metabolism insulin infusion
comparison of two analgesic pretreatment techniques before spinal needle insertion for pain reduction and maternal satisfaction level assessment in women undergoing lscs.

Conditions: Anesthesia, Spinal; Pain; Pregnancy; Cesarean Section

Summary: nowadays lower segment cesarean sections are preferably carried out under regional anesthesia due to multiple advantages. local infiltration of lidocaine or any other anesthetic is used before lumber puncture in many centers to reduce needle stick pain. emla (eutectic mixture of local anesthetic) cream is the combination of lidocaine and prilocaine which have been effectively used in few studies to reduce needle prick pain. we would like to see which analgesic pretreatment is superior in terms of reducing pain of spinal needle insertion and have better maternal satisfaction levels.

objectives: to compare the pain reduction and maternal satisfaction levels of two analgesic pretreatment modalities on pain reduction of spinal needle insertion i.e. 2% lidocaine infiltration and emla in patients undergoing elective lscs. hypothesis: analgesic pre-treatment with emla is superior to local skin infiltration with lidocaine

Eligibility criteria:
inclusion criteria: * all adult women undergoing elective lscs under spinal anesthesia exclusion criteria: * bmi of more than 35 kg/m2 * contraindication to spinal anesthesia * spinal deformity * refusal of regional anesthesia * patients with a history of back surgery * confirmed allergy to local anesthetics * more than three attempts of needle insertion for inducing spinal anesthesia
the therapeutics effects of yoga in individuals with parkinson's disease

Conditions: Parkinson's Disease

Summary: to determine if yoga is beneficial in improving physical function quality of life and medical status in people with parkinson's disease

this pilot study is a randomized controlled study of 20-30 individuals with parkinson's disease will have a control group with no training and a research group with yoga training. the control group will have the opportunity to attend yoga training of the same intensity after the study is completed. the effects of yoga will not be on the control group. data on physical function will be derived from assessments including strength, balance, flexibility, rom. gait, posture and functional analysis performed in the georgia holland cardiopulmonary and neuromuscular research lab. questionnaires related to quality of life, depression and falls will determine psychological impact or yoga training. vital signs, pulmonary function tests and blood draws will be done in the general clinical research center (gcrc) and protein analysis will be done in the diabetes research lab.

Eligibility criteria:
inclusion criteria: * parkinson's disease * stage 1-3 hoehn \& yahr exclusion criteria: * decline in immune function * 6 month joint surgery * spinal fusions * decline in mental status measured by folstein mini mental status exam

Keywords: parkinson's disease
preventive treatment of tacrolimus ointment in children with atopic dermatitis

Conditions: Moderate/Severe Atopic Dermatitis

Summary: to assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (de) in paediatric patients over a period of 6 months.

this study includes three periods. first a screening period of up to one week. second an open-label treatment period of up to six weeks where all participants apply tacrolimus ointment. third an open-label disease control period of up to six months where half of the participants apply tacrolimus ointment and the other half of the participants do not apply treatment.

Eligibility criteria:
inclusion criteria: 1. diagnosed as ad according to williams diagnostic criteria. 2. moderate or severe atopic dermatitis according to the criteria of rajka and langeland 3. at least approximately 10 % of body area 4. patient is able to reach the centre within 3 days in case of a disease exacerbation. 5. patient's legal representative(s) has/have given written informed consent. if the patient is capable of understanding the purposes and risks of the trial, written informed consent has been obtained from the patient as well

Keywords: tacrolimus protopic pediatric atopic dermatitis china
to look at the characteristics of synovial fluid and cartilage matrix in osteoarthritic knee after hyaluronic acid injection

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to identify novel imaging markers for characterizing the biochemical profiles in synovial fluid and cartilage matrix in oa knee joints after intra-articular ha (euflexxa) injection using high field nmr and mri techniques. we hypothesize that: 1. high-field hrmas nmr spectroscopy will provide sensitive measures for biochemical changes within knee synovial fluid after ha injection; 2. baseline hrmas spectroscopy, in particular n-acetyl peaks, as well as early changes of glutamate will predict patient response of pain relief after ha injection; 3. mr cartilage t1p and t2 quantifications will provide sensitive measures for biochemical changes within knee cartilage matrix after ha injection. specifically cartilage t1p and t2 will decrease in patients who respond to the treatment, indicating potential beneficial effects of ha injection to cartilage preservation.


Eligibility criteria:
inclusion criteria: * age 18 to 80 years * symptomatic knee oa as defined by the american college of rheumatology criteria * kellgren-lawrence grade i, ii or iii on prior x-rays (take within 6 months of screening visit) * knee pain score \>40 mm on a 100 mm visual analogue scale for \> 15 days in the last month * nsaids permitted if the dose has been stable for at least one month prior to baseline and stays stable during the study * have been recommended for euflexxa treatment by physician * knee effusion based on clinical exam or imaging exclusion criteria: * any contraindication to mri (pregnancy, metallic fragments in the eyes, vascular clips, pacemakers etc) * history of knee replacement * known sensitivity or allergy to any component of euflexxa * inflammatory arthritis * previously received viscosupplementation therapy within 6 months of study enrollment * intra-articular injection of corticosteroid to study joint within the past 3 months * arthroscopic or open surgery within the previous 12 months or planned surgery to the study joint * concomitant medications of oral/parenteral corticosteroids * morbid obesity defined as body mass index (bmi) \>40 kg/m2 * active malignancy; an active systemic infection; recent high impact or high energy trauma (clinically defined) to the study joint * large knee effusion based on clinical exam or imaging

Keywords: knee osteoarthritis (oa) hyaluronic acid injection
topotecan in combination with gemcitabine in patients with platinum-resistant ovarian carcinoma

Conditions: Ovarian Cancer

Summary: topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. this trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum -resistant ovarian cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed ovarian adenocarcinoma * patients had to have received a front-line, platinum- based chemotherapy regimen * patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer. this category also will include patients with disease progression within six months of completing the most recent platinum-based chemotherapy * patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area, or increased ca 125 * a \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment * age \> 18 years old * performance status (who) 0-2 * life expectancy of at least three months * adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3) * adequate liver (bilirubin \< 1.5 times upper limit of normal and sgot/sgpt \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl) * informed consent exclusion criteria: * pregnant or nursing * psychiatric illness or social situation that would preclude study compliance * other concurrent uncontrolled illness * other invasive malignancy within the past 5 years except nonmelanoma skin cancer

Keywords: cancer; ovarian cancer; recurrent ovarian cancer platinum-resistant
smartphone-based mobility assessment and individualized exercise programs for patients with frozen shoulder

Conditions: Frozen Shoulder

Summary: this study was to investigate the reliability and validity of the smartphone goniometer app to measure shoulder rom in a modified position for patients with frozen shoulder, and compare the intervention effect and adherence to home exercise between the smartphone and traditional paper hangouts.

this study was to investigate the reliability and validity of the smartphone goniometer app to measure shoulder rom in a modified position for patients with frozen shoulder, and compare the intervention effect and adherence to home exercise between the smartphone and traditional paper hangouts. the outcome measure including shoulder range of motion, pain condition, home exercise adherence and satisfaction of smartphone program

Eligibility criteria:
inclusion criteria: * gradual shoulder pain and stiffness at least 4 months * loss of active and passive shoulder mobility, shoulder external rotation \<45 degree * ability to use the smartphone exclusion criteria: * normal shoulder mobility * diagnostic shoulder osteoarthritis * nerve pain * injection of corticosteroids in 3 months

Keywords: frozen shoulder smartphone home exercise program range of motion